NURIX THERAPEUTICS, INC. Operating Lease, Right-of-Use Asset, Amortization Expense
NURIX THERAPEUTICS, INC. (NRIX) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $3.17 million for the 6-month period ending 2026-05-31, per its 10-Q filed 2026-07-09.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-07-09
- NURIX THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-05-31 was $1.59M, a 44.13% decline year-over-year.
- NURIX THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-02-28 was $1.58M, a 11.14% decline year-over-year.
- NURIX THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-11-30 was $2.51M, a 43.16% increase year-over-year.
- NURIX THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-08-31 was $2.97M, a 69.63% increase year-over-year.
- NURIX THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $10.12M, a 42.28% increase from fiscal 2024.
- NURIX THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $7.11M, a 16.16% increase from fiscal 2023.
- NURIX THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $6.12M, a 12.13% increase from fiscal 2022.
- NURIX THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $5.46M, a 65.83% increase from fiscal 2021.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-05-31 | $1.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-09 | $3.17M 10-Q · filed 2026-07-09 | $5.69M derived: sum of 3 quarters · filed 2026-07-09 | $8.66M derived: sum of 4 quarters · filed 2026-07-09 |
| 2026-02-28 | $1.58M 10-Q · filed 2026-04-08 | $4.09M derived: sum of 2 quarters · filed 2026-04-08 | $7.06M derived: sum of 3 quarters · filed 2026-04-08 | $9.92M derived: sum of 4 quarters · filed 2026-07-09 |
| 2025-11-30 | $2.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28 | $5.48M derived: sum of 2 quarters · filed 2026-01-28 | $8.34M derived: sum of 3 quarters · filed 2026-07-09 | $10.12M 10-K · filed 2026-01-28 |
| 2025-08-31 | $2.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-09 | $5.83M derived: sum of 2 quarters · filed 2026-07-09 | $7.61M 10-Q · filed 2025-10-09 | $9.36M derived: sum of 4 quarters · filed 2026-07-09 |
| 2025-05-31 | $2.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-09 | $4.63M 10-Q · filed 2026-07-09 | $6.39M derived: sum of 3 quarters · filed 2026-07-09 | $8.14M derived: sum of 4 quarters · filed 2026-07-09 |
| 2025-02-28 | $1.78M 10-Q · filed 2026-04-08 | $3.53M derived: sum of 2 quarters · filed 2026-04-08 | $5.28M derived: sum of 3 quarters · filed 2026-04-08 | $7.04M derived: sum of 4 quarters · filed 2026-04-08 |
| 2024-11-30 | $1.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28 | $3.51M derived: sum of 2 quarters · filed 2026-01-28 | $5.27M derived: sum of 3 quarters · filed 2026-01-28 | $7.11M 10-K · filed 2026-01-28 |
| 2024-08-31 | $1.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-09 | $3.51M derived: sum of 2 quarters · filed 2025-10-09 | $5.36M 10-Q · filed 2025-10-09 | $7.18M derived: sum of 4 quarters · filed 2026-01-28 |
| 2024-05-31 | $1.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-09 | $3.60M 10-Q · filed 2025-07-09 | $5.43M derived: sum of 3 quarters · filed 2026-01-28 | $6.86M derived: sum of 4 quarters · filed 2026-01-28 |
| 2024-02-29 | $1.84M 10-Q · filed 2025-04-08 | $3.67M derived: sum of 2 quarters · filed 2026-01-28 | $5.10M derived: sum of 3 quarters · filed 2026-01-28 | $6.54M derived: sum of 4 quarters · filed 2026-01-28 |
| 2023-11-30 | $1.82M derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28 | $3.26M derived: sum of 2 quarters · filed 2026-01-28 | $4.69M derived: sum of 3 quarters · filed 2026-01-28 | $6.12M 10-K · filed 2026-01-28 |
| 2023-08-31 | $1.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-11 | $2.87M derived: sum of 2 quarters · filed 2024-10-11 | $4.30M 10-Q · filed 2024-10-11 | $5.72M derived: sum of 4 quarters · filed 2025-01-28 |
| 2023-05-31 | $1.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-11 | $2.87M 10-Q · filed 2024-07-11 | $4.28M derived: sum of 3 quarters · filed 2025-01-28 | $5.71M derived: sum of 4 quarters · filed 2025-01-28 |
| 2023-02-28 | $1.43M 10-Q · filed 2024-04-10 | $2.85M derived: sum of 2 quarters · filed 2025-01-28 | $4.28M derived: sum of 3 quarters · filed 2025-01-28 | $5.63M derived: sum of 4 quarters · filed 2025-01-28 |
| 2022-11-30 | $1.42M derived: 10-K 12 month − 10-Q 9 month · filed 2025-01-28 | $2.85M derived: sum of 2 quarters · filed 2025-01-28 | $4.20M derived: sum of 3 quarters · filed 2025-01-28 | $5.46M 10-K · filed 2025-01-28 |
| 2022-08-31 | $1.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-12 | $2.78M derived: sum of 2 quarters · filed 2023-10-12 | $4.04M 10-Q · filed 2023-10-12 | $4.89M derived: sum of 4 quarters · filed 2023-10-12 |
| 2022-05-31 | $1.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-13 | $2.61M 10-Q · filed 2023-07-13 | $3.46M derived: sum of 3 quarters · filed 2023-07-13 | $4.33M derived: sum of 4 quarters · filed 2023-07-13 |
| 2022-02-28 | $1.26M 10-Q · filed 2023-04-13 | $2.12M derived: sum of 2 quarters · filed 2023-04-13 | $2.98M derived: sum of 3 quarters · filed 2023-04-13 | $3.81M derived: sum of 4 quarters · filed 2023-04-13 |
| 2021-11-30 | $853.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-09 | $1.72M derived: sum of 2 quarters · filed 2023-02-09 | $2.55M derived: sum of 3 quarters · filed 2023-02-09 | $3.29M 10-K · filed 2023-02-09 |
| 2021-08-31 | $863.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-06 | $1.70M derived: sum of 2 quarters · filed 2022-10-06 | $2.44M 10-Q · filed 2022-10-06 | |
| 2021-05-31 | $834.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-07 | $1.58M 10-Q · filed 2022-07-07 | ||
| 2021-02-28 | $742.00K 10-Q · filed 2022-04-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |